Drugs / 19-28z/IL-18 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06287528 | Feb 2024 → Feb 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 19-28z/IL-18 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06287528 ↗ |
| Known as | 19-28z/IL-18 | “The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study.” NCT06287528 ↗ |
| Modality | Cell therapy | “the CAR T-cell therapy that participants will receive during the study” NCT06287528 ↗ |
| Target | CD19 | “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells” NCT06287528 ↗ |